Fibrinolytic therapy in acute stroke

Current Cardiology Reviews

Volumn 6, Issue 3, 2010, Pages 218-226

  Millán, Mònica ^a   Dorado, Laura ^a   Dávalos, Antoni ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cardioembolic stroke; Intra arterial thrombolysis; Mechanical thrombectomy; Stroke subtype; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; DESMOTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR; PROUROKINASE; RATEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BLOOD CLOT LYSIS; BLOOD VESSEL PERFORATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CATHETER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG SAFETY; ECHO PLANAR IMAGING; EMBOLISM; ENDOVASCULAR SURGERY; FIBRINOLYTIC THERAPY; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MECHANICAL THROMBECTOMY; MECHANICAL THROMBOLYSIS; META ANALYSIS; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMAL HEMATOMA; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECANALIZATION; SALVAGE THERAPY; STROKE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRASOUND;

EID: 77956528828     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310791658758     Document Type: Article

References (65)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and strokestatistics: 2008 update-a report from the American Heart Association Statistics Committee and Stroke StatisticsSubcommittee. Circulation 2008;117: e25-146.
2. Cocho D, Belvís R, Martí-Fábregas J, et al. Reasons for exclusionfor thrombolytic therapy following acute ischemic stroke.Neurology 2005; 22: 719-20.
3. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-73.
4. The National Institute of Neurological Disorders and Stroke rt-PAStroke Study Group.Tissue plasminogen activator for acuteischemic stroke. N Engl J Med 1995; 333:1581-7.
5. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
6. Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, TomsickTA, for the IMS I and II Investigators. Good clinical outcome afterischemic stroke with successful revascularization is time-dependent. Neurology 2009; 73:1066-1072.
7. Mishra NK, Albers GW, Davis SM, et al. Mismatch-based delayedthrombolysis: a meta-analysis. Stroke 2010; 41:e25-33.
8. Gasparotti R, Grassi M, Marghindian D, et al. Perfusion CT inpatients with acute ischemic stroke treated with intra-arterialthrombolysis: predictive value of infarct core size on clinicaloutcome. Am J Neuroradiol 2009; 30: 722-7.
9. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis withalteplase for acute ischaemic stroke in the Safe Implementation ofThrombolysis in Stroke-Monitoring Study (SITS-MOST): anobservational study. Lancet 2007; 369:275-82.
10. Tsivgoulis G, Molina CA, Eggers J, et al. Safety and efficacy ofultrasound-enhanced thrombolysis: a meta-analysis of randomizedand nonrandomized studies. Stroke 2008; 39:593-594.
11. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhancedthrombolysis for acute ischemic stroke. N Engl J Med 2004; 351:2170-8.
12. Hacke W, Kaste M, Bluhmki E, et al, for the European Cooperative Acute Stroke Study (ECASS) investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
13. Wahlgren N, Ahmed N, Dávalos A, et al, SITS investigators.Thrombolysis with alteplase 3-4.5 hours after acute ischemic stroke(SITS-ISTR): an observational study. Lancet 2008; 372:1303-9.
14. del Zoppo GJ, Saver CJ, Jauch EC, Adams HP, on behalf of the American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A scince Advisory form the American Heart Association/ American Stroke Association. Stroke 2009; 40: 2945-8
15. th, 2008.
16. Röther J, Shellinger PD, Gass A, et al. Effect of intravenousthrombolysis on MRI parameters and functional outcome in acutestroke 6hours. Stroke 2002; 36: 1452-6.
17. Ribó M, Molina CA, Rovira A, et al. Safety and efficacy ofintravenous tissue plasminogen activator stroke treatment in the 3-to 6-hour window using multimodal transcraneal Doppler/MRIselection protocol. Stroke 2005; 36: 602-6.
18. Shellinger PD, Jansen O, Fiebach JB, et al. Monitoring intravenousrecombinant tissue plasminogen activator thrombolysis for acuteischemic stroke with diffusion and perfusion MRI. Stroke 2000; 31:1318-28.
19. Parsons MW, Barber PA, Chalk J, et al. Diffusion and perfusion weighted MRI response to thrombolysis in stroke. Ann Neuro 2002; 51: 28-37
20. Schellinger PD, Thomalla G, Fiehler J, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007; 38: 2640-5
21. Nighoghossian N, Hermier M, Adeleine P, et al. Baseline magneticresonance imaging parameters and stroke outcome in patient streated by intravenous tissue plasminogen activator. Stroke 2003;34: 458-63.
22. Chalela JA, Kang DW, Luby M, et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute strokein the thrombolysis era. Ann Neurol 2004; 55: 105-12.
23. Thomalla G, Schwark C, Sobesky J, et al. MRI in Acute StrokeStudy Group of the German Competence Network Stroke. Outcome and symptomatic bleeding complications of intravenousthrombolysis within 6 hours in MRI-selected stroke patients:comparison of a German multicenter study with the pooled data ofATLANTIS, ECASS and NINDS alteplase trials. Stroke 2006; 37:852-8.
24. Hacke W, Albers G, Al-Rawi Y, et al for the DIAS studygroup. The desmoteplase in acute ischemic stroke trial (DIAS). Aphase II MRI-based 9-hour window acute stroke thrombolysis trialwith intravenous desmoteplase. Stroke 2005; 36: 66-73.
25. Furlan AJ, Eyding D, Albers GW, et al, DEDAS investigators. Dose escalation of desmoteplase for acute ischemic stroke(DEDAS): evidence of safety and efficacy 3 to 9 hours after strokeonset. Stroke 2006; 37: 1227-31.
26. Hacke W, Furlan AJ, Al-Rawi Y, et al. DIAS-2 - A prospectiverandomised double-blind placebo-controlled study of intravenous desmoteplase in patients with acute ischemic stroke selected byMagnetic Resonance Perfusion-Diffusion Weighted Imaging (MR-PI-DWI) or Perfusion Computed Tomography (PC T). Lancet Neurol 2009; 8:141-50.
27. Davis SM, Donnan GA, Parsons MW, et al EPITHETinvestigators. Effects of alteplase beyond 3 h after stroke in theEchoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): aplacebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309.
28. De Silva DA, Fink JN, Christensen S, et al. Assessing reperfusionand recanalization as markers of clinical outcomes afterintravenous thrombolysis in the Ecoplanar Imaging ThrombolyticEvaluation Trial (EPITHET). Stroke 2009; 40: 2872-4.
29. Kidwell C, Starkman S, Jahan R, et al. Pretreatment MRIpenumbral pattern predicts good clinical outcome followingmechanical embolectomy. Stroke 2004; 35: 294.
30. Albers GW, Thijs VN, Wechler L, et al. Magnetic resonanceimaging profiles predict clinical response to early reperfusion: Thediffusion and perfusion imaging evaluation for understandingstroke evolution (DEFUSE) study. Ann Neurol 2006; 29(6): 862-7.
31. Olivot JM, Mlynash M, Thijs VN, et al. Relationships betweeninfarct growth, clinical outcome, and early recanalization indiffusion and perfusion imaging for understanding stroke evolution(DEFUSE). Stroke 2008; 39: 2257-63.
32. Furlan A, Higashida R, Wechsler L, et al. Intra-arterialProurokinase for Acute Ischemic Stroke. The PROACT II Study: A Randomized Controlled Trial. JAMA 1999; 282: 2003-11.
33. Ogawa A, Mori E, Minematsu K, et al. Randomized Trial ofIntraarterial Infussion of Urokinase Within 6 Hours of MiddleCerebral Artery Stroke. The Middle Cerebral Artery EmbolismLocal Fibrinolytic Intervention Trial (MELT) Japan. Stroke 2007;38: 2633-9.
34. Saver JL. Intra-arterial fibrinolysis for acute ischemic stroke: themessage of melt. Stroke 2007; 38: 2627-8.
35. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30: 2598-605.
36. The IMS study investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The interventional management of stroke study. Stroke 2004; 35: 904-12
37. The IMS study investigators. The interventional management of stroke (IMS) II study. Stroke 2007; 38: 2127-35.
38. Vernisck EJ, Do HM, Albers GW, Tong DC, Marks MP.Mechanical thrombectomy for acute stroke. AJNR 2005; 26: 875-9.
39. Ramee SR, Subramanian R, Felberg RA, et al. Catheter-based treatment for patients with acute ischemic stroke ineligible for intravenous thrombolysis. Stroke 2004; 35: 109-11.
40. Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: a phase 1study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 2004; 35: 2848-54.
41. Smith WS, Sung G, Starkman S, for the MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy inacute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8.
42. Smith WS, Sung G, Saver J, for the Multi MERCI Investigators. Mechanical thrombectomy for acute ischemic stroke: final resultsof the Multi MERCI trial. Stroke 2008; 39: 1205-12.
43. Bose A, Henkes H, Alfke K, for the Penumbra Phase 1 Stroke Trial Investigators. The Penumbra System: a mechanical device for thetreatment of acute stroke due to thromboembolism. Am J Neuroradiol 2008; 29: 1409-13.
44. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotalstroke trial: safety and effectiveness of a new generation ofmechanical devices for clot removal in intracranial large vesselocclusive disease. Stroke 2009; 40: 2761-8.
45. Stead LG, Rachel M, Gilmore M, Bellolio MF, Rabinstein AA,Decker WW. Percutaneous clot removal devices in acute ischemicstroke. A systemic review and meta-analysis. Arch Neurol 2008;65: 1024-30.
46. Lin R, Vora N, Zaidi S, et al. Mechanical approaches combinedwith intra-arterial pharmacological therapy are associated withhigher recanalization rates than either intervention alone inrevacularization of acute carotid terminus occlusion. Stroke 2009;40: 2092-7.
47. Natarajan SK, Snyder KV, Siddiqui AH, Ionita CC, Hopkins LN, Levy EI. Safety and effectiveness of endovascular therapy after 8hours of acute ischemic stroke onset and wake-up strokes. Stroke 2009; 40: 3269-74.
48. Zaidi S, Lin R, Vora N, Gupta R, et al. Intra-arterial treatment foracute ischemic strokes due to intracranial large vessel occlusionbeyond 8 hours-preliminary results. Abstr Cerebrovasc Dis 2008;25 (suppl 2): 42.
49. Mahon BR, Nesbit GM, Barnwell SL, et al. North Americanclinical experience with the EKOS MicroLysUS infusion catheterfor the treatment of embolic stroke. Am J Neuroradiol 2003; 24:534-8.
50. Babarro EG, Rego AR, González-Juanatey JR. Cardioembolic stroke: call for a multidisciplinary approach. Cerebrovasc Dis 2009; 27 (Suppl 1): 82-7.
51. Ueda T, Sakaki S, Kumon Y, Ohta S. Multivariate analysis ofpredictive factors related to outcome at 6 months after intra-arterialthrombolysis for acute ischemic stroke. Stroke 1999; 30: 2360-5.
52. Molina CA, Montaner J, Abilleira S, et al. Timing of spontaneousrecanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001; 32: 1079-84.
53. Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagictransformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996; 46:1373-8.
54. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA stroketrial. Stroke 1997; 28: 2119-25.
55. Molina CA, Montaner J, Abilleira S, et al. Time course of tissueplasminogen activator-induced recanalization in acute cardioem-bolic stroke. A case-control study. Stroke 2001; 32: 2821-7.
56. Christou I, Alexandrov AV, Burgin WS, et al. Timing ofrecanalization after tissue plasminogen activator therapydetermined by transcranial Doppler correlates with clinicalrecovery form ischemic stroke. Stroke 2000; 31: 1812-6.
57. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterialocclusion identified by transcranial Doppler (TCD) predicts theresponse of intravenous thrombolysis for stroke. Stroke 2007; 38:948-54.
58. Urbach H, Hartmann A, Pohl C, et al. Local intra-arterial thrombolysis in the carotid territory: does recanalization depend on the thromboembolus type?. Neuroradiology 2002; 44: 695-9.
59. Blinc A, Planinsic G, Keber D, et al. Dependence of blood clotlysis on the mode of transport of urokinase into the clot: a magnetic resonance imaging study in vitro. Thromb Haemost 1991; 65: 549-52
60. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
61. Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabin J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004; 35: 486-90.
62. Soinne L, Saimanen E, Malmberg-Céder K, et al. Association ofthe fibrinolytic system and hemorheology with symptoms inpatients with carotid occlusive disease. Cerebrovasc Dis 2005; 20:172-9.
63. Zunker P, Schick A, Padró T, Kienast J, Phillips A, Ringelstein EB. Tissue plasminogen activator and plasminogen activator inhibitorin patients with acute ischemic stroke: relation to stroke etiology.Neurol Res 1999; 21: 727-32.
64. Marder VJ, Chute DJ, Stakman S, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006; 37: 2086-93.
65. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC.Efficacy of IV tissue plasminogen activator in acute stroke. Does stroke subtype really matter?. Neurology 2003; 61: 71-5.